Due to its crucial involvement in lipid production, ACLY inhibitors, initially designed for metabolic conditions like hypercholesterolemia and type 2 diabetes, are now being explored as potential treatments for cancer (Granchi, 2018; Ray et al., 2019). This evidence concerns the gene ACLY and cancer.